The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

China's volume-based procurement policy and US tariffs have forced companies with large businesses in China to reset their ...

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming, nonetheless, and the industry ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus ...

The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

The South Korean firm said that its CURECA system offers walkaway PCR testing with 24/7 operation without human intervention ...

The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

The test simultaneously detects and differentiates between SARS-CoV-2, influenza A/B, and respiratory syncytial virus.